59440--3/17/2006--VECTOR_GROUP_LTD

related topics
{product, liability, claim}
{competitive, industry, competition}
{control, financial, internal}
{condition, economic, financial}
{debt, indebtedness, cash}
{loss, insurance, financial}
{personnel, key, retain}
{tax, income, asset}
{loan, real, estate}
{stock, price, share}
{customer, product, revenue}
Liggett faces intense competition in the domestic tobacco industry. Liggett s business is highly dependent on the discount cigarette segment. Liggett s market share is susceptible to decline. The domestic cigarette industry has experienced declining unit sales in recent periods. Litigation and regulation will continue to harm the tobacco industry. Liggett may have additional payment obligations under the Master Settlement Agreement and its other settlement agreements with the states. Liggett has significant sales to a single customer. Liggett may be adversely affected by recent legislation to eliminate the federal tobacco quota system. Excise tax increases adversely affect cigarette sales. Vector Tobacco is subject to risks inherent in new product development initiatives. The actual costs and savings associated with restructurings of our tobacco business may differ materially from amounts we estimate. New Valley is subject to risks relating to the industries in which it operates. Potential new investments we may make are unidentified and may not succeed. We depend on our key personnel. While we believe our controls systems are effective, there are inherent limitations in all control systems, and misstatements due to error or fraud may occur and not be detected.

Full 10-K form ▸

related documents
59440--3/16/2007--VECTOR_GROUP_LTD
57725--9/13/2006--LANNETT_CO_INC
10456--2/19/2009--BAXTER_INTERNATIONAL_INC
59440--2/29/2008--VECTOR_GROUP_LTD
1035976--3/13/2009--FIRST_NATIONAL_COMMUNITY_BANCORP_INC
715579--3/14/2008--ACNB_CORP
874710--9/26/2008--ALLIED_HEALTHCARE_PRODUCTS_INC
739944--3/15/2007--MEDTOX_SCIENTIFIC_INC
739944--3/11/2008--MEDTOX_SCIENTIFIC_INC
874710--9/28/2006--ALLIED_HEALTHCARE_PRODUCTS_INC
739944--3/10/2009--MEDTOX_SCIENTIFIC_INC
1050007--11/29/2007--NUTRACEUTICAL_INTERNATIONAL_CORP
42542--2/17/2009--GOODRICH_CORP
931336--3/1/2007--DEAN_FOODS_CO
42542--2/19/2008--GOODRICH_CORP
918112--9/28/2010--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/
918112--8/31/2009--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/
10456--2/23/2010--BAXTER_INTERNATIONAL_INC
922237--3/26/2008--ENOVA_SYSTEMS_INC
1050007--11/20/2008--NUTRACEUTICAL_INTERNATIONAL_CORP
42542--2/16/2010--GOODRICH_CORP
1091596--2/26/2007--CYTOMEDIX_INC
10456--2/26/2008--BAXTER_INTERNATIONAL_INC
810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC
862668--9/29/2008--ESCALON_MEDICAL_CORP
10081--8/30/2006--BARR_PHARMACEUTICALS_INC
827156--10/15/2007--ZILA_INC
350846--3/28/2007--SUPREME_INDUSTRIES_INC
922237--4/2/2007--ENOVA_SYSTEMS_INC
1019650--3/14/2008--CENTRUE_FINANCIAL_CORP